FDA Panel Narrowly Endorses Mela Sciences’ Melanoma Detection System
This article was originally published in The Gray Sheet
Executive Summary
An FDA advisory panel Nov. 18 narrowly endorsed Mela Sciences’ MelaFind melanoma detection system, voting 8-7, with one abstention, that the benefits outweigh any risks.
You may also be interested in...
Mela Sciences Cites Binding Study Protocol Pact As Key To FDA Reversal On MelaFind PMA
A rare binding study protocol agreement with FDA was a crucial factor in Mela Sciences’ successful campaign to reverse an initial “not approvable” determination for the firm’s melanoma detection device, according to CEO Joseph Gulfo.
Mela Sciences Cites Binding Study Protocol Pact As Key To FDA Reversal On MelaFind PMA
A rare binding study protocol agreement with FDA was a crucial factor in Mela Sciences’ successful campaign to reverse an initial “not approvable” determination for the firm’s melanoma detection device, according to CEO Joseph Gulfo.
Citizen Petition: FDA Reneged On Binding Agreement For Melanoma Device
Mela Sciences has filed a citizen petition asking FDA Commissioner Margaret Hamburg to enforce a “binding protocol agreement” and investigate regulators’ conduct as the company struggles to obtain PMA approval for its MelaFind melanoma detection device.